Combination therapy with bosentan and metformin in PAH‐CHD patients improved exercise capacity and pulmonary haemodynamics, compared with bosentan alone. Additionally, in vitro decreased pulmonary artery contraction is possibly related to increased AMPK phosphorylation. Here, PRKAA1 is linked to coronary artery disorder.